- Home
- SNDL vs AUTL Comparison
SNDL vs AUTL Comparison
Compare SNDL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- AUTL
- Stock Information
- Founded
- SNDL 2006
- AUTL 2014
- Country
- SNDL Canada
- AUTL United Kingdom
- Employees
- SNDL N/A
- AUTL N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNDL Health Care
- AUTL Health Care
- Exchange
- SNDL Nasdaq
- AUTL Nasdaq
- Market Cap
- SNDL 638.2M
- AUTL 625.4M
- IPO Year
- SNDL 2019
- AUTL 2018
- Fundamental
- Price
- SNDL $2.41
- AUTL $1.38
- Analyst Decision
- SNDL Strong Buy
- AUTL Strong Buy
- Analyst Count
- SNDL 1
- AUTL 5
- Target Price
- SNDL $5.00
- AUTL $9.12
- AVG Volume (30 Days)
- SNDL 3.9M
- AUTL 4.6M
- Earning Date
- SNDL 11-04-2025
- AUTL 11-11-2025
- Dividend Yield
- SNDL N/A
- AUTL N/A
- EPS Growth
- SNDL N/A
- AUTL N/A
- EPS
- SNDL N/A
- AUTL N/A
- Revenue
- SNDL $692,339,389.00
- AUTL $29,934,000.00
- Revenue This Year
- SNDL $5.30
- AUTL $634.25
- Revenue Next Year
- SNDL $4.11
- AUTL $93.16
- P/E Ratio
- SNDL N/A
- AUTL N/A
- Revenue Growth
- SNDL 3.54
- AUTL 185.17
- 52 Week Low
- SNDL $1.15
- AUTL $1.11
- 52 Week High
- SNDL $2.74
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- SNDL 59.57
- AUTL 28.28
- Support Level
- SNDL $2.33
- AUTL $1.34
- Resistance Level
- SNDL $2.62
- AUTL $1.46
- Average True Range (ATR)
- SNDL 0.13
- AUTL 0.10
- MACD
- SNDL -0.04
- AUTL 0.01
- Stochastic Oscillator
- SNDL 36.54
- AUTL 11.11
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.